An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents
- PMID: 16990018
- DOI: 10.1016/j.vascn.2006.07.001
An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents
Abstract
Introduction: Integrated in vivo models applying intracerebral microdialysis in conjunction with automated serial blood sampling in conscious, freely moving rodents are an attractive approach for pharmacokinetic (PK) and simultaneous pharmacokinetic/pharmacodynamic (PK/PD) investigations of CNS active drugs within the same animal. In this work, the ability to obtain and correlate data in this manner was evaluated for the selective serotonin (5-HT) reuptake inhibitor (SSRI) escitalopram.
Methods: An instrumented rat model equipped with an intracerebral hippocampal microdialysis probe and indwelling arterial and venous catheters was applied in the studies. Concomitant with brain microdialysis, serial blood sampling was conducted by means of an automated blood sampling device. The feasibility of the rat model for simultaneous PK/PD investigations was examined by monitoring plasma and brain extracellular concentrations of escitalopram along with SSRI-associated pharmacological activity, monitored as changes in brain 5-HT levels and plasma corticosterone levels.
Results: Combining intracerebral microdialysis and automated blood sampling did not cause any detectable physiological changes with respect to basal levels of plasma corticosterone or brain 5-HT levels. Furthermore, the PK of escitalopram in hippocampus following intravenous injection was not influenced by the presence of vascular catheters. Conversion of escitalopram dialysate concentrations into absolute extracellular levels by means of in vivo retrodialysis was verified by the no-net-flux method, which gave similar recovery estimates. The PK of escitalopram could be characterized simultaneously in plasma and the hippocampus of conscious, freely moving rats. Concomitantly, the modulatory and functional effects of escitalopram could be monitored as increases in brain 5-HT and plasma corticosterone levels following drug administration.
Discussion: The applicability of intracerebral microdialysis combined with arterial blood sampling was demonstrated for simultaneous PK/PD investigations of escitalopram in individual rats under non-stressful conditions. Together, these temporal relationships provide multiple PK/PD information in individual animals, hence minimizing inter-animal variation using a reduced number of animals.
Similar articles
-
Pharmacokinetic/pharmacodynamic feedback modelling of the functional corticosterone response in rats after acute treatment with escitalopram.Basic Clin Pharmacol Toxicol. 2007 Mar;100(3):182-9. doi: 10.1111/j.1742-7843.2006.00029.x. Basic Clin Pharmacol Toxicol. 2007. PMID: 17309522
-
Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels.Eur J Pharm Sci. 2006 Dec;29(5):394-404. doi: 10.1016/j.ejps.2006.08.004. Epub 2006 Aug 12. Eur J Pharm Sci. 2006. PMID: 17014998
-
[Mechanisms of action of antidepressants: new data from Escitalopram].Encephale. 2003 May-Jun;29(3 Pt 1):259-65. Encephale. 2003. PMID: 12876551 French.
-
[Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].Encephale. 2007 Dec;33(6):965-72. doi: 10.1016/j.encep.2007.11.001. Epub 2007 Dec 11. Encephale. 2007. PMID: 18789789 Review. French.
-
Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice.Neuropharmacology. 2008 Nov;55(6):1006-14. doi: 10.1016/j.neuropharm.2008.08.001. Epub 2008 Aug 12. Neuropharmacology. 2008. PMID: 18761360 Review.
Cited by
-
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.J Pharm Pharm Sci. 2014;17(1):34-91. J Pharm Pharm Sci. 2014. PMID: 24735761 Free PMC article.
-
Differential Blood-Brain Barrier Transport and Cell Uptake of Cyclic Peptides In Vivo and In Vitro.Pharmaceutics. 2023 May 16;15(5):1507. doi: 10.3390/pharmaceutics15051507. Pharmaceutics. 2023. PMID: 37242750 Free PMC article.
-
Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice.Br J Pharmacol. 2008 Sep;155(2):276-84. doi: 10.1038/bjp.2008.243. Epub 2008 Jun 16. Br J Pharmacol. 2008. PMID: 18552871 Free PMC article.
-
P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.Neuropsychopharmacology. 2013 Oct;38(11):2209-19. doi: 10.1038/npp.2013.120. Epub 2013 May 14. Neuropsychopharmacology. 2013. PMID: 23670590 Free PMC article.
-
Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane.J Neurosci. 2023 Mar 29;43(13):2222-2241. doi: 10.1523/JNEUROSCI.1519-22.2022. Epub 2023 Mar 3. J Neurosci. 2023. PMID: 36868853 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources